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Background
MGA271 is an Fc optimized, humanized IgG1 monoclonal
antibody targeting B7-H3 (CD276), a member of the B7
family, and is currently undergoing Phase I testing. The Fc
domain is engineered for enhanced binding to the activat-
ing FcgR, CD16A, and decreased binding to the inhibitory
FcgR, CD32B. B7-H3 exhibits limited expression on
normal tissues, but is highly expressed in a broad range of
tumors, including melanoma (M), squamous cell cancer of
the head and neck (SCCHN) and non-small cell lung can-
cer (NSCLC). The correlation between B7-H3 overexpres-
sion and poor prognosis in certain cancers suggests a role
for B7-H3 in tumor immune escape. Although ipilimumab
(anti-CTLA-4) is approved for the treatment of melanoma,
only a minority of patients respond clinically. Combined
targeting of CTLA-4 and PD-1, using ipilimumab and
nivolumab (anti-PD-1), demonstrated synergistic antitu-
mor activity, albeit with substantially increased toxicity
over either agent alone. B7-H3 and CTLA-4 play distinct
immunoregulatory roles and it appears that complemen-
tary mechanisms could be engaged by targeting these
molecules. These include modulation of T-cell function,
including the function of regulatory T-cells, and engage-
ment of both innate and adaptive immunity. Further,
B7-H3 expression in normal tissues is limited, suggesting
that B7-H3 may not be a key driver in maintaining
self-tolerance, thus reducing the potential for induction of
immune-related AEs (irAEs) in patients treated with
MGA271 compared to molecules such as anti-CTLA-4.
Based on these observations, we hypothesized that
MGA271 could potentiate the immunoregulatory and
antitumor activity of ipilimumab, with a more favorable
overall safety profile than other combinations such as anti-
CTLA-4/anti-PD-1.
Methods
This multi-center, open-label trial (NCT02381314) enrolls
patients with advanced B7-H3-expressing SCCHN, M, or
NSCLC (squamous and non-squamous histology).
Progression on previous checkpoint inhibitor therapy is
allowed. To investigate whether B7H3 contributes to
“immunologic escape” in patients treated with checkpoint
inhibitors, M patients are required to have progressed on
a checkpoint inhibitor within 12 weeks of enrollment.
Using a 3+3 +3 dose escalation design, successive cohorts
of patients will be treated with escalating doses of weekly
IV MGA271 (starting dose 3 mg/kg) up to 1 year in com-
bination with standard doses of IV ipilimumab (3 mg/kg)
Q3 weeks x 4 doses. Cohort expansions will be enrolled at
the maximum tolerated dose, and include patients with M,
HNSC and NSCLC (16 patients/cohort). Major objectives
for this study include characterization of safety, tolerabil-
ity, pharmacokinetics, pharmacodynamics, and preliminary
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